All studies
Cardiology · EHR · UK
Althunian 2020
Atrial fibrilation
ITT, PP, ATNon-inferiorityAcademia, Government2/5 disclosures
Comparisons
3
In the analysis
3
all comparisons pooled
Target trials
1
Emulations reported
3
2 treatments
Design and methods
- Estimand
- ITT, PP, AT
- Design hypothesis
- Non-inferiority
- Matching / weighting
- None
- Analysis method
- Cox PH
- Missing data
- Complete case
- Covariates adjusted
- 32
- DAG
- No
- QBA
- No
Data and sample
- Data type
- EHR
- Data sources
- 1
- Geography
- UK
- Eligible sample
- 25473
- Treated
- 4008
- Control
- 21465
- Emulations
- 3
- Treatments compared
- 2
Transparency
- Protocol
- No pre-registration
- Preprint
- No preprint
- Data availability
- Unavailable
- Code availability
- Unavailable
- Conflicts of interest
- Declared: None
- Funding
- Declared: Public
- Funders
- Saudi Food and Drug Authority (SFDA)
The 0-5 count records which disclosures are present. It is not a quality score: a data link does not establish that the data are reusable.
Provenance
- Review key
- 2020_Althunian_AtrialFibrilation
- DOI
- https://doi.org/10.1002/pds.5065
- Affiliations
- Utrecht University, Dutch Medicines Evaluation Board, University Medical Center Utrecht
- Sector
- Academia, Government
- Target trials (study level)
- ROCKET AF
- Registration
- NCT00403767